RAYALDEE
Total Payments
$6.0M
Transactions
34,576
Doctors
5,040
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $173,970 | 6,573 | 2,079 |
| 2023 | $191,091 | 8,244 | 2,425 |
| 2022 | $225,564 | 7,298 | 2,180 |
| 2021 | $4.2M | 7,826 | 2,220 |
| 2020 | $1.2M | 4,635 | 1,610 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.2M | 344 | 86.8% |
| Food and Beverage | $362,447 | 21,172 | 6.1% |
| Education | $211,941 | 12,921 | 3.5% |
| Consulting Fee | $93,241 | 25 | 1.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $79,879 | 54 | 1.3% |
| Honoraria | $39,923 | 35 | 0.7% |
| Travel and Lodging | $3,848 | 25 | 0.1% |
Payments by Type
Research
$5.2M
344 transactions
General
$791,279
34,232 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 | OPKO Pharmaceuticals, LLC | $3.4M | 1 |
| Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI | OPKO Pharmaceuticals, LLC | $819,905 | 0 |
| An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency | OPKO Pharmaceuticals, LLC | $429,247 | 0 |
| AN OPEN-LABEL, REPEATED-DOSE SAFETY, EFFICACY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF ORAL CTAP101 CAPSULES, IMMEDIATE- RELEASE (IR) CALCIFEDIOL, HIGH-DOSE CHOLECALCIFEROL, AND PARICALCITOL PLUS LOW-DOSE CHOLECALCIFEROL IN PATIENTS WITH SECONDARY HYPERPARATHYROIDISM, STAGE 3 OR 4 CHRONIC KIDNEY DISEASE AND VITAMIN D INSUFFICIENCY | OPKO Pharmaceuticals, LLC | $179,217 | 0 |
| Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI | OPKO Pharmaceuticals, LLC | $161,084 | 0 |
| Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency | OPKO Pharmaceuticals, LLC | $70,651 | 0 |
| SAFETY AND EFFICACY OF RAYALDEE FOR TREATING MILD TO MODERATE COVID-19 | OPKO Pharmaceuticals, LLC | $35,886 | 0 |
| A MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF CTAP101 EXTENDED-RELEASE CAPSULES TO TREAT SECONDARY HYPERPARATHYROIDISM IN PEDIATRIC SUBJECTS OF AGES 8 TO <18 YEARS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE AND VITAMIN D INSUFFICIENCY. | OPKO Pharmaceuticals, LLC | $26,250 | 0 |
| Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism | OPKO Pharmaceuticals, LLC | $20,205 | 1 |
| SAFETY, EFFICACY, PK AND PD OF CTAP101 (CALCIFEDIOL) ER CAPSULES FOR SHPT IN HD PATIENTS VDI | OPKO Pharmaceuticals, LLC | $11,000 | 0 |
| Repeated-dose Safety, Efficacy, PK and PD of CTAP101, IR Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With SHPT, CKD 3-4 and VDI | OPKO Pharmaceuticals, LLC | $2,915 | 0 |
Top Doctors Receiving Payments for RAYALDEE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Waltham, MA | $5.2M | 348 |
| , MD | Pediatric Endocrinology | Morristown, NJ | $49,218 | 1 |
| , DO | Critical Care Medicine | Hinsdale, IL | $45,724 | 46 |
| , DO | Nephrology | Evanston, IL | $30,538 | 29 |
| , M.D | Internal Medicine | San Antonio, TX | $26,199 | 155 |
| , M.D | Specialist | New York, NY | $17,213 | 2 |
| , M.D | Nephrology | Poland, OH | $15,512 | 23 |
| , MD | Nephrology | Avenel, NJ | $14,817 | 82 |
| , MD | Pediatric Endocrinology | Philadelphia, PA | $11,483 | 1 |
| , DO | Nephrology | Neptune, NJ | $11,220 | 21 |
| , DO | Nephrology | Allentown, PA | $10,411 | 46 |
| , M.D | Family Medicine | Jackson, MI | $9,000 | 1 |
| , M.D | Nephrology | Evergreen Park, IL | $5,058 | 1 |
| Jill Lindberg | — | Metairie, LA | $2,440 | 5 |
| , MD | Nephrology | Great Neck, NY | $2,058 | 66 |
| , MD | Nephrology | New Hyde Park, NY | $1,975 | 157 |
| , MD | Nephrology | Fort Lauderdale, FL | $1,930 | 27 |
| , MD | Nephrology | New Hyde Park, NY | $1,801 | 120 |
| , MD | Endocrinology, Diabetes & Metabolism | Reno, NV | $1,659 | 138 |
| , MD | Nephrology | Brighton, MA | $1,659 | 122 |
| , D.O | Family Medicine | Lynbrook, NY | $1,579 | 79 |
| , D.O | Endocrinology, Diabetes & Metabolism | Lake Success, NY | $1,579 | 78 |
| , DO | Family Medicine | North New Hyde Park, NY | $1,438 | 80 |
| , M.D | Nephrology | Inglewood, CA | $1,375 | 5 |
| , M.D | Nephrology | Orange, CA | $1,291 | 84 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $6.0M
- Total Doctors 5,040
- Transactions 34,576
About RAYALDEE
RAYALDEE is a drug associated with $6.0M in payments to 5,040 healthcare providers, recorded across 34,576 transactions in the CMS Open Payments database. The primary manufacturer is OPKO Pharmaceuticals, LLC.
Payment data is available from 2020 to 2024. In 2024, $173,970 was paid across 6,573 transactions to 2,079 doctors.
The most common payment nature for RAYALDEE is "Unspecified" ($5.2M, 86.8% of total).
RAYALDEE is associated with 11 research studies, including "Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19" ($3.4M).